Mounjaro Weight Loss Drug Linked to Increased Adverse Reactions and Deaths in 2025
In 2025, the weight loss drug Mounjaro saw a significant rise in adverse reactions, with a 300 percent increase in reported cases compared to the previous year. According to data from the Medicines and Healthcare products Regulatory Agency (MHRA) Yellow Card Scheme, there were 40,245 reported reactions, including 6,755 classified as serious and 71 resulting in death. The most common side effects were gastrointestinal disorders, with 37,546 reports, 19 of which were fatal. The drug, used for weight loss and type two diabetes management, has been linked to severe side effects such as nausea, diarrhea, and abdominal cramps. A notable case involved Karen Coe, who experienced extreme reactions after her first injection, leading to hospitalization. The manufacturer, Eli Lilly and Company, emphasized patient safety and encouraged reporting adverse events. The MHRA updated product information to include a risk of severe acute pancreatitis, a condition that can lead to serious complications. 
